Publications by authors named "G P Lidgard"
Unlabelled: The multi-target stool DNA (mt-sDNA) test screens for colorectal cancer by analyzing DNA methylation/mutation and hemoglobin markers to algorithmically derive a qualitative result. A new panel of highly discriminant candidate methylated DNA markers (MDM) was recently developed. Performance of the novel MDM panel, with hemoglobin, was evaluated in a simulated screening population using archived stool samples weighted to early-stage colorectal cancer and prospectively collected advanced precancerous lesions (APL).
View Article and Find Full Text PDFDespite considerable research efforts, pancreatic cancer is associated with a dire prognosis and a 5-year survival rate of only 10%. Early symptoms of the disease are mostly nonspecific. The premise of improved survival through early detection is that more individuals will benefit from potentially curative treatment.
View Article and Find Full Text PDFPurpose: We have previously identified tissue methylated DNA markers (MDMs) associated with pancreatic ductal adenocarcinoma (PDAC). In this case-control study, we aimed to assess the diagnostic performance of plasma MDMs for PDAC.
Experimental Design: Thirteen MDMs (, and ) were identified on the basis of selection criteria applied to results of prior tissue experiments and assays were optimized in plasma.
Article Synopsis
- The study focused on identifying methylated DNA markers (MDMs) in colorectal tumors associated with Lynch syndrome (LS) to help distinguish neoplasia.
- Using next-generation sequencing, researchers analyzed DNA from 53 LS colorectal cases and controls, and validated findings with methylation-specific PCR assays on 197 samples.
- The MDMs found showed strong potential for improving screening and surveillance methods for colorectal neoplasia, distinguishing LS tumors from sporadic cases effectively.
Purpose: We aimed to assess the concordance of colorectal cancer-associated methylated DNA markers (MDM) in primary and metastatic colorectal cancer for feasibility in detection of distantly recurrent/metastatic colorectal cancer in plasma.
Experimental Design: A panel of previously discovered colorectal cancer-associated MDMs was selected. MDMs from primary and paired metastatic colorectal cancer tissue were assayed with quantitative methylation-specific PCR.